Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of...

Related Keywords

United States ,Israel ,Chicago ,Illinois ,American ,Christie Corbett ,Arnob Banerjee ,Yael Cohen ,Satu Glawe ,Early Development Oncology ,Companies Of Johnson ,Janssen Pharmaceutical Companies Of Johnson ,National Comprehensive Cancer Network ,None Of The Janssen Pharmaceutical Companies ,American Society Of Clinical Oncology ,Janssen Biotech Inc ,National Cancer Institute ,American Cancer Society ,Johnson ,Janssen Research Development ,Exchange Commission ,Other Administration Reactions ,Aviv Sourasky Medical Center ,Janssen Pharmaceutical Companies ,European Commission ,Hematology Institute ,European Medicines Agency ,Clinical Oncology ,Annual Meeting ,Myeloma Unit ,Tel Aviv Sourasky Medical Center ,Confidence Interval ,Not Estimable ,Global Medical Head ,Janssen Research ,Drug Administration ,National Comprehensive Cancer ,Orphan Drug Designation ,Breakthrough Therapy Designation ,Biologics License Application ,Risk Evaluation ,Mitigation Strategy ,Release Syndrome ,Fetal Toxicity ,Prescribing Information ,Boxed Warning ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Results From ,With Teclistamab ,Simultaneously Targeting ,Refractory Multiple Myeloma ,American Society ,Participants With Relapsed ,Refractory Multiple ,Janssen Biotech ,European Medicines ,Accessed June ,Clinical Practice Guidelines ,Comprehensive Cancer ,Natl Acad Sci United ,Plasma Cell ,Accessed September ,Statistics About Multiple Myeloma ,Janssen Oncology ,